EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Frontage Holdings's enterprise value is HK$3,313 Mil.
Frontage Holdings's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was HK$169 Mil. Therefore, Frontage Holdings's EV-to-EBITDA for today is 19.57.
The historical rank and industry rank for Frontage Holdings's EV-to-EBITDA or its related term are showing as below:
HKSE:01521'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.29 Med: 22.29 Max: 72.88
Current: 19.57
During the past 8 years, the highest EV-to-EBITDA of Frontage Holdings was 72.88. The lowest was 7.29. And the median was 22.29.
HKSE:01521's EV-to-EBITDA is ranked worse than 65.65% of 457
companies
in the Biotechnology industry
Industry Median: 9.79
vs HKSE:01521: 19.57
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Frontage Holdings EV-to-EBITDA Historical Data
The historical data trend for Frontage Holdings's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Frontage Holdings's EV-to-EBITDA
For the Biotechnology subindustry, Frontage Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Frontage Holdings's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Frontage Holdings's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Frontage Holdings's EV-to-EBITDA falls into.
Frontage Holdings's current Enterprise Value is HK$3,313 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Frontage Holdings's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was HK$169 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Frontage Holdings's PE Ratio for today is calculated as:
Frontage Holdings's share price for today is HK$1.26.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Frontage Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.040.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Frontage Holdings's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Frontage Holdings (HKSE:01521) Business Description
Frontage Holdings Corp is a contract research organization providing integrated, scientifically driven research, analytical and development services. Geographically the group operates in both PRC and North America. The services provided in the North American segment, include Bioanalytical, CMC, DMPK and Safety and Toxicology services in the USA and Canada. The service offered in PRC includes Bioanalytical, Bioequivalence and CMC services in the PRC. Further, it also provides bioanalytical services, which are offered throughout the drug discovery and development process both in the United States and China.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:01521 has been successfully added to your 